David Bwambok

Dr. David Bwambok


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Chemosensors
Verified
Journal Article
Open access
PDF file
Sayo FakayodeSayo Fakayode
Sayo Fakayode
PBPamlea Nicole Brady
Pamlea Nicole Brady
CGCidya Grant
Cidya Grant
VNVivian Fernand Narcisse
Vivian Fernand Narcisse
PFPeter Rosado Flores
Peter Rosado Flores
DBDavid Bwambok
David Bwambok
Pharmaceutical opioids are intravenously or orally administered analgesics. While they are effective in relieving chronic and acute pain, their narrow window of therapeutic use contributes to the high occurrence of abuse. The associated abuse of this family of drugs can be correlated to the increase in dependency, overdose, and death of users. The negative effects of opioids extend beyond the physical and psychological effects experienced by the user to their unregulated synthesis and sale, which contribute to socioeconomic challenges and are a biproduct of this global public health epidemic. From clinical to point-of-care applications, the detection and real-time monitoring of this family of drug is critical in the fight to decrease abuse and improve use in clinical settings. Chromatographic separations and chromatography–mass spectrometry are traditional methods of opioid analyses, but the high cost, long analysis time, and absence of portability highlight the need for the development of fast, in situ, point-of-care analysis, or of community drug monitoring services. This review highlights recent electrochemical and optical (FTIR, Raman, colorimetric, and fluorescent) advances and biosensors for pharmaceutical and illicit opioid analysis. Specifically, an emphasis is placed on the detection of opioids and their metabolites in biological samples and in vitro cellular assays for clinical diagnosis and forensic applications. The challenges and prospects of the role of electrochemical sensors, biosensors, and optical sensors for opioid analysis in promoting clinical diagnosis, forensic study, point-of-care, and community drug monitoring services to reduce harm are also provided.

7 July 2025 in Forensic Sciences
Verified
Journal Article
Open access
PDF file
JMJoel Eliu Richard Moss
Joel Eliu Richard Moss
KHKathryn Hamory
Kathryn Hamory
RMRobert Moreland
Robert Moreland
COCarolyn B. Oakley
Carolyn B. Oakley
DBDavid Bwambok
David Bwambok
VNVivian Fernand Narcisse
Vivian Fernand Narcisse
Background/Objectives: Over the past few decades, controlled substance abuse in drug-facilitated sexual assaults (DFSAs) has significantly increased worldwide, leading to an urgency to develop rapid and selective drug detection methods for field use (i.e., on-spot detection). Currently, techniques for detecting DFSA drug-associated samples are laborious and require skilled personnel to analyze/interpret the results. Moreover, most DFSA-associated drugs have a short half-life, making them more challenging to detect promptly. For instance, the timely detection of gamma-hydroxybutyrate (GHB) has been of ultimate concern for decades due to its fast elimination from the body. This study describes the development of a fluorescent ionic liquid nanosensor that can be used to rapidly detect GHB in the field. Methods: Trihexyltetradecylphosphonium fluorescein (THP2FL) ionic liquid was synthesized and evaluated for its potential application in detecting GHB. THP2FL nanoparticles in deionized water were synthesized with a size of 199 nm by a reprecipitation method. Results: The addition of GHB to THP2FL nanoparticles resulted in up to a 60% increase in fluorescence intensity and a 79% increase in absorbance. These results suggest potential applications for using the fluorescent THP2FL nanoparticles to detect GHB. The sensor’s selectivity was tested on compounds structurally similar to GHB, and the results showed that 1,4-butanediol (a precursor of GHB) is a potentially interfering species. Conclusion: This fluorescent technique allows for field deployable sensors, which would benefit screening GHB onsite.

4 September 2025 in Sensors
Verified
Journal Article
Open access
PDF file
SFSayo Fakayode
Sayo Fakayode
DBDavid Bwambok
David Bwambok
SBSouvik Banerjee
Souvik Banerjee
PRPRATEEK RAI
PRATEEK RAI
RORonald Okoth
Ronald Okoth
UBUfuoma Benjamin
Ufuoma Benjamin
Nitrosamines, including N-nitroso diethylamine (NDEA) have emerged as pharmaceutical impurities and carcinogenic environmental contaminants of grave public health safety concerns. This study reports on the preparation and first use of cysteine–gold nanoparticles (CysAuNPs) for colorimetric detection of NDEA in human serum albumin (HSA) under physiological conditions. Molecular docking (MD) and molecular dynamic simulation (MDS) were performed to probe the interaction between NDEA and serum albumin. UV–visible absorption and fluorescence spectroscopy, dynamic light scattering (DLS), and transmission electron microscopy (TEM) imaging were used to characterize the synthesized CysAuNPs. These CysAuNPs show a UV–visible absorbance wavelength maxima (λmax) at 377 nm and emission λmax at 623 nm. Results from DLS measurement revealed the CysAuNPs’ uniform size distribution and high polydispersity index of 0.8. Microscopic imaging using TEM showed that CysAuNPs have spherical to nanoplate-like morphology. The addition of NDEA to HSA in the presence of CysAuNPs resulted in a remarkable increase in the absorbance of human serum albumin. The interaction of NDEA–CysAuNPs–HSA is plausibly facilitated by hydrogen bonding, sulfur linkages, or by Cys–NDEA-induced electrostatic and van der Waal interactions. These are due to the disruption of the disulfide bond linkage in Cys–Cys upon the addition of NDEA, causing the unfolding of the serum albumin and the dispersion of CysAuNPs. The combined use of molecular dynamic simulation and colorimetric experiment provided complementary data that allows robust analysis of NDEA in serum samples. In addition, the low cost of the UV–visible spectrophotometer and the easy preparation and optical sensitivity of CysAuNPs sensors are desirable, allowing the low detection limit of the CysAuNPs sensors, which are capable of detecting as little as 0.35 µM NDEA in serum albumin samples, making the protocol an attractive sensor for rapid detection of nitrosamines in biological samples.

4 May 2026 in Sensors
Verified
Journal Article
Open access
PDF file
SFSayo Fakayode
Sayo Fakayode
DBDavid Bwambok
David Bwambok
EAEris Arth
Eris Arth
UBUfuoma Benjamin
Ufuoma Benjamin
RHRebecca Huisman
Rebecca Huisman
PFPeter Rosado Flores
Peter Rosado Flores
A continued interest in developing a low-cost, rapid screening method for quantifying Hg (II) and As (III) in biological samples stems from the toxic effects of human exposure to these heavy metal ions. This study reports the use of cysteine-capped gold nanoparticles (CysAuNPs) for chemical sensing, colorimetric detection, and quantification of As (III) and Hg (II) ions in human serum albumin (HSA) under physiological conditions. Zeta potential measurements indicated that the CysAuNPs have a negative surface charge, which was decreased in the presence of HSA and reversed to a positive value upon binding of As (III) and Hg (II) metal ions. Circular dichroism (CD) spectroscopy revealed changes in HSA conformation upon binding to As (III) and Hg (II) ions. X-ray fluorescence enables rapid qualitative screening for As (III) and Hg (II) ions before colorimetric quantification. The figures of merit (R2 ≥ 0.940) and the low detection limits (0.05 ppm for As (III) ions and 0.02 ppm for Hg (II)) in serum albumin demonstrate the high sensitivity of the method. The developed calibration curves correctly quantified the concentration of As (III) and Hg (II) ions of independently prepared test validation samples in HSA with an accuracy of ≥95% over a period of seven months without recalibrations, demonstrating the stability of CysAuNPs in solution and the robustness of the method for analysis of As (III) and Hg (II) ions in serum albumin.